Workflow
Fibroblast Activation Protein (FAP)
icon
Search documents
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
Globenewswire· 2025-04-28 11:00
Core Insights - Avacta Therapeutics announced promising preclinical results for its second pre|CISION candidate, FAP-EXd (AVA6103), which shows tumor growth inhibition and durable complete responses in therapy-resistant models [1][5] Group 1: Pre|CISION Platform - The pre|CISION platform targets fibroblast activation protein-alpha (FAPα), which is overexpressed in a wide range of solid tumors, allowing for localized drug activation [2][6] - Avacta's proprietary pre|CISION chemistry enhances drug efficacy while minimizing systemic toxicity by activating potent drugs selectively at the tumor site [2][11] Group 2: AVA6103 (FAP-EXd) Highlights - AVA6103 delivers the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface, optimizing pharmacokinetics and minimizing systemic toxicity [4][11] - Despite exatecan's short half-life of 9 hours, FAP-EXd can achieve high tumor concentrations with projected exposures exceeding 60 hours from a single dose [4][5] Group 3: Efficacy and Future Plans - FAP-EXd has shown significant tumor growth inhibition and durable complete responses in multiple patient-derived xenograft models, including those resistant to topoisomerase I inhibition [5] - The company anticipates submitting an investigational new drug (IND) application in December 2025 and starting the first-in-human study in Q1 2026 [5] Group 4: Collaboration and Research Insights - Avacta's collaboration with Tempus has confirmed consistent FAP expression across therapy lines and identified optimal patient populations for pre|CISION medicines [7] - The broad expression of FAP in human solid tumors supports the potential of the pre|CISION platform to deliver effective therapies across multiple indications [6][7]